Hester Biosciences Ltd — Board/Management Information 2021

Jun 8, 2021

08.06.2021

To,	To,
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers,	Exchange Plaza,
Dalal Street,	Bandra - Kurla Complex,
Mumbai - 400 001	Bandra (E), Mumbai - 400 051

Symbol: HESTERBIO

Respected Sir / Madam:

Scrip Code: 524669

Subject: Outcome of Board Meeting

This is with reference to our letter dated 27.05.2021 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Audited Financial Results for the quarter and year ended on 31.03.2021 and to consider declaration of dividend, if any, on the equity shares of the Company, for the financial year 2020-21.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the followings:

• 1. Audited Standalone and Consolidated Financial Results for the quarter and year ended 31.03.2021, as recommended by Audit Committee and the Audited Standalone and Consolidated Financial Statements for the year ended 31.03.2021.
• 1. Recommended dividend of 100% that is INR 10 per equity share of INR 10 each for the financial year 2020-21, subject to approval of members in the ensuing Annual General Meeting.
• 1. Resignation of Mr. Chetas Patel from the post of Chief Financial Officer (KMP) of the Company with effect from the close of the office hours on 08.06.2021.
• 1. Appointment of Mr. Nikhil Jhanwar as a Chief Financial Officer (KMP) of the Company with effect from 09.06.2021.
• 1. Re-appointment of Ernst & Young LLP as an Internal Auditor of the Company for the financial year 2021-22.

Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended time to time), we hereby state that the Statutory Auditors of the Company, Chadulal M. Shah & Co., Chartered Accountants (FRN: 101698W) have issued an Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31.03.2021.

The details, as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR / CFD / CMD / 4 /2015 dated 9 September 2015, including the brief profile of the Key Managerial Personnel referred as above (in case of appointment/reappointment), are given as Annexures respectively.

We attach herewith:

• 1. The approved standalone and consolidated audited financial results and auditors reports.
• 1. Press Release issued in this regard

We would be publishing the extract of results in the newspaper as per SEBI (Listing Obligations and

Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 10:45 a.m. and concluded at 11:50 a.m.

You are requested to take the above information on your record.

Sincerely, For Hester Biosciences Limited

Rajiv Gandhi CEO & Managing Director DIN: 00438037

Annexure-1: The details of resignation of Chief Financial Officer of the Company:

Sr.	Particulars	Details
1	Name of Key Managerial	Mr. Chetas patel
	Personnel
2	Reason for change viz.	Resignation
	appointment or
	resignation
3	Date of Resignation	With effect from the close of the office hours on 08.06.2021
4	Brief profile	Not Applicable
	(in case of appointment)

Annexure-2: The details of appointment of Chief Financial Officer of the Company:

Sr.	Particulars	Details
1	Name of Key ManagerialPersonnel	Mr. Nikhil Jhanwar
2	Reason for change viz.appointment orresignation	Upon resignation of Mr. Chetas Patel as a Chief Financial Officer of theCompany, Mr. Nikhil Jhanwar has been appointed as Chief FinancialOfficer of the Company.
3	Date of appointment /& Term of appointment;	With effect from 09.06.2021, Appointment as a Chief Financial Officer(Key Managerial Personnel)
4	Brief profile(in case of appointment)	Mr. Nikhil Jhanwar is a chartered accountant and holds degree ofBachelor of Commerce from Mumbai University. Nikhil has more than16 years of experience, particularly in the fields of auditing, accountingadvice, taxation. Nikhil was earlier working with S R B C & CO LLP

For Hester Biosciences Limited

Rajiv Gandhi CEO & Managing Director DIN: 00438037